Supporting a potential role of these proteins in AML, some TAS2Rs were found to be significantly down-regulated in poor-prognosis AML groups, such as TP53-mut and TET2-mut patients, which might be a strategy adopted by AML cells to evade possible growth-suppression factors, as demonstrated in breast cancer cells [238]. This evidence concerns the gene TET2 and acute myeloid leukemia.